 WESTLAKE VILLAGE, Calif., Dec. 07, 2020 GLOBE NEWSWIRE -- Arcutis Biotherapeutics, Inc. Nasdaq: ARQT, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that the last participant has completed the 8-week treatment period in DERMIS-1 and DERMIS-2, the Companys pivotal Phase 3 clinical trials evaluating ARQ-151 topical roflumilast cream as a potential topical treatment for plaque psoriasis. 